Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Solutions
  2. Products
  3. Insights
  4. About
  5. Careers
  6. Contact Us
MAIN/search
MAIN/Solutions
Solutions/
SOLUTIONS
  • Research & Development
  • Real World Evidence
  • Commercialization
  • Safety & Regulatory Compliance
  • Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
THERAPEUTIC AREAS

Impacting People's Lives

"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.

LEARN MORE
Harness the power to transform clinical development

Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.

Research & Development Overview
Research & Development Quick Links
Real World Evidence. Real Confidence. Real Results.

Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.

REAL WORLD EVIDENCE OVERVIEW
Real World Evidence Quick Links
See markets more clearly. Opportunities more often.

Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.

COMMERCIALIZATION OVERVIEW
Commercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.

Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.

COMPLIANCE OVERVIEW
Safety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.

When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.

TECHNOLOGIES OVERVIEW
Technology Quick Links
MAIN/Products
Products/
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
REAL WORLD PRODUCTS

CASE STUDY

"Data in a Day

LEARN MORE
MAIN/Insights
Insights/
BLOGS, WHITE PAPERS & CASE STUDIES

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

DISCOVER INSIGHTS
THE IQVIA INSTITUTE

An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.

SEE LATEST REPORTS

INSTITUTE REPORT

"Digital Health Trends 2024 - Implications for Research and Patient Care

READ MORE

EMEA Insights

"IQVIA thought leadership with a focus on EMEA.

Learn more

WHITE PAPER

"DCTs Deliver Big ROI

LEARN MORE

WHITE PAPER

"Capturing value at scale: The $4 billion RWE imperative

LEARN MORE
MAIN/About
About/
FEATURED INNOVATIONS
  • IQVIA Connected Intelligence™
  • IQVIA Healthcare-grade AI™
  • Human Data Science Cloud
  • IQVIA Innovation Hub
  • Decentralized Trials
  • Patient Experience Solutions with Apple devices
WHO WE ARE
NEWS & RESOURCES

INVESTOR RELATIONS

"Visit our investor relations site for more information.

LEARN MORE
Unlock your potential to drive healthcare forward

By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.

LEARN MORE
IQVIA AI is Healthcare-grade AI

Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.

LEARN MORE

Your healthcare data deserves more than just a cloud.

The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.

LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships

The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.

LEARN MORE
Proven, faster DCT solutions

IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.

LEARN MORE
IQVIA Patient Experience Solutions with Apple devices

Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.

LEARN MORE
MAIN/Careers
Careers/
WORKING AT IQVIA

Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.

LEARN MORE
LIFE AT IQVIA

Careers, culture and everything in between. Find out what’s going on right here, right now.

LEARN MORE

WE’RE HIRING

"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.

SEARCH JOBS
MAIN/Contact Us
Contact Us/
Institute Report
Global Oncology Trends 2024: Outlook to 2028
Annual trend report from the IQVIA Institute for Human Data Science
May 28, 2024
To download files, please accept Functional Cookies. These cookies provide enhanced functionality for a better user experience.

Report Summary

Latest estimates indicate that the number of patients affected by cancer will increase dramatically through the middle of the century across all regions of the world. At the same time, the innovation ecosystem that discovers, develops, and delivers breakthrough therapies in entire new areas of science is operating near peak levels. Rising incidence, increasing numbers of treated patients, and the resulting expected growth in spending in this area will trigger an array of complex challenges over the next several years that are reflected in the trends highlighted in this report.

Our research profiles latest available data on cancer incidence and survival, the current state of research and development activity in oncology, including key mechanisms, targets and cancer types being investigated. We also look at metrics of clinical development productivity. As more novel cancer medicines are launched, patient access and use of those drugs vary widely around the world and by some measures the gaps between the science and patients is expanding. Trends in the use of novel mechanisms in specific cancer types are reported here as well as current expectations for how spending dynamics will play out over the next five years.

Key findings:
  • Cancer incidence is expected to rise significantly through 2050, particularly in lower-income countries, potentially increasing by more than 12 million new cases annually to 32 million.
  • Global spending on cancer medicine increased to $223 billion in 2023, $25 billion more than 2022, and is projected to reach $409 billion by 2028.
  • In 2023, 25 oncology novel active substances (NASs) were launched globally, making a total of 193 since 2014 – however, large geographic variations exist in availability of these medicines.
  • More than 2,000 new oncology clinical trials started in 2023 with novel modalities and significant promise for cancer treatment, including cell and gene therapies, antibody-drug conjugates, multispecific antibodies, and radioligand therapies.
  • Cancer treatments have increased 9% annually since 2019 but the pace of bringing novel therapies to patients is uneven due to differences in biomarker testing rates, adoption of novel therapies and lack of infrastructure capacity to deliver some of the most advanced therapies.

 

Other findings:


Novel oncology mechanisms, especially cell and gene therapies, ADCs, and multispecific antibodies have risen to 25% of trial starts
  • Oncology research and development has seen an increasing focus on targeted drugs with innovative mechanisms of action for treatment of cancers over the last decade.
  • Trials for hematological cancers declined 17% in 2023, while clinical development activity for solid tumor cancers remained unchanged after a peak in 2021.
  • PD-1/PD-L1 checkpoint inhibitors, which saw significant growth over the last decade, have begun to taper off in recent years, indicating a crowded market and switch to even newer targeted molecules.

A total of 125 oncology NASs have launched globally in the past 5 years and 259 over 20 years with large geographic variations
  • Globally there were 125 oncology NASs in the past five years, nearly double the 67 in the prior five years, while the number of launches by key geographies shifted considerably.
  • China accelerated from just 24 NAS in 2014–2018 to 83 in the last five years and passed the U.S. to be the country with the most novel oncology drug launches.
  • Notably, China had 37 NAS in the past five years that have not launched in other markets to date, beginning a pattern of domestic-first or domestic-only innovation not previously seen.

The use of checkpoint inhibitors has risen rapidly in major markets with variations on a per capita basis and some lagging
  • The wide adoption of PD-1/PD-L1 checkpoint inhibitors reflects their strong efficacy across a range of solid tumors, including several with tissue-agnostic approvals triggering their use with biomarker testing results.
  • Usage has varied considerably across countries, with the U.S., Germany, and France using two to three times more of these drugs per capita than the UK and South Korea.
  • Many of the major European countries have highly similar rates of usage to other developed markets, including the Nordic countries.

Cancer medicine spending rose to $223Bn globally in 2023 and is expected to reach $409Bn by 2028
  • Cancer medicine spending rose to $223Bn globally in 2023, with 74% focused in the major developed markets (the United States, EU4+UK and Japan), which has remained stable over the last five years.
  • Spending growth in these major developed markets is expected to be similar in the next five years to the last five, with the five-year CAGR through 2028 expected to be 11-14% for both the U.S. and EU4+UK and 4–7% for Japan.
  • U.S. spending on oncology has risen from $65Bn in 2019 to $99Bn in 2023, representing 45% of global spending, and is expected to grow to nearly $180Bn in 2028.

Related solutions

Oncology

Focus oncology development on the patient, manage trial complexity, and increase predictability and speed.

Clinical Research & Development Solutions

Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.

Real World Evidence

IQVIA is using vast quantities of data in powerful new ways. See how we can help you tap into information from past trials, patient reported outcomes and other sources to accelerate your research.

Contact Us